Bone Pain Treatment Global Market Report 2025

The bone pain treatment market size has grown strongly in recent years. It will grow from $5.62 billion in 2024 to $6.05 billion in 2025 at a compound annual growth rate (CAGR) of 7.6%. The growth during the historic period can be attributed to the rising prevalence of chronic conditions such as osteoporosis and arthritis, a surge in bone disorder cases, an expanding elderly population, increasing awareness regarding bone health, and a higher incidence of cancer-related bone metastases.

The bone pain treatment market size is expected to see strong growth in the next few years. It will grow to $8.01 billion in 2029 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to the increasing demand for targeted biologic therapies for bone pain, rising preference for non-invasive treatment options, the expanding adoption of personalized medicine in bone pain management, growing demand for over-the-counter pain relievers, and improved access to healthcare in emerging markets. Key trends anticipated during this period include the integration of artificial intelligence in bone pain management, the use of virtual reality for pain relief, advancements in treatments for osteoporotic bone pain, the development of technology-enhanced pain relief devices, cross-therapy integration, and the incorporation of robotics in surgical interventions.

The increasing prevalence of osteoporosis is expected to propel the growth of the bone pain treatment market going forward. Osteoporosis is a condition marked by reduced bone density and strength, making bones more fragile and susceptible to fractures. This condition is becoming more common, primarily due to the aging global population, as bone density typically decreases with age. Bone pain treatments play a critical role in managing osteoporosis by relieving associated discomfort, improving mobility, and supporting better quality of life. For instance, in June 2024, the Australian Institute of Health and Welfare reported that approximately 853,600 individuals in Australia were living with osteoporosis or osteopenia in 2022, with the disease contributing to 2,659 deaths that year. Therefore, the rising prevalence of osteoporosis is significantly driving the demand for effective bone pain treatments.

Major companies operating in the bone pain treatment market are focusing on developing innovative solutions, such as prescription wearable devices, to deliver targeted pain relief. These medically approved devices are worn on the body and offer therapies like electrical stimulation or vibration to alleviate bone pain by enhancing circulation, reducing inflammation, or disrupting pain signals. For instance, in May 2025, Osteoboost Health Inc., a US-based medical equipment manufacturer, launched Osteoboost, the first FDA-cleared wearable device specifically designed for individuals with low bone density. This wearable belt delivers low-amplitude, high-frequency vibration therapy (20-40 Hz) to the spine and hips and is intended to slow the loss of bone density and strength in postmenopausal women with osteopenia. Designed for daily 30-minute use during normal activities, Osteoboost has demonstrated clinical efficacy in preserving bone health without significant adverse events. The device integrates a motorized vibration pack, pressure sensor, and accelerometers to ensure precise and safe therapy delivery.

In November 2023, Boston Scientific Corporation, a US-based biotechnology company, acquired Relievant Medsystems Inc. for $850 million. This strategic acquisition was aimed at expanding Boston Scientific’s chronic pain management portfolio and reinforcing its leadership in the interventional pain space. By integrating Relievant’s innovative, FDA-cleared solutions, the company seeks to enhance patient access to effective treatments and improve clinical outcomes. Relievant Medsystems Inc., also based in the US, specializes in treating chronic low back pain, with a particular focus on vertebrogenic pain, offering targeted therapies that address the underlying source of pain.

Major players in the bone pain treatment market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche Ltd., Merck and Co. Inc., Bayer AG, Sanofi S.A, Bristol-Myers Squibb Company, Novartis International AG, GSK plc, Medtronic plc, Eli Lilly and Company, Amgen Inc., Stryker Corporation, Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Endo International plc, Amneal Pharmaceuticals Inc., Marksans Pharma Limited, and APS Materials Inc.

North America was the largest region in the bone pain treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in bone pain treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the bone pain treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Bone pain treatment involves medical interventions aimed at relieving discomfort or aching in the bones, which may result from conditions such as fractures, infections, cancer, or chronic illnesses. These treatments typically encompass medications, physical therapy, and, in some cases, surgical procedures to target the root cause and mitigate pain.

The primary categories of bone pain treatment include pharmacological treatments, non-pharmacological approaches, and surgical interventions. Pharmacological treatments involve the use of drugs to prevent, manage, or treat medical conditions by influencing specific biological functions. The drug classes commonly employed include analgesics, antidepressants, anticonvulsants, and corticosteroids. Bone pain is generally treated for conditions such as injuries, infections, myalgia, and tumors. Treatment options are distributed via direct sales, retail pharmacies, and online pharmacies, and are used by end users such as hospitals, clinics, and homecare settings.

The bone pain treatment market research report is one of a series of new reports that provides bone pain treatment market statistics, including the bone pain treatment industry's global market size, regional shares, competitors with the bone pain treatment market share, detailed bone pain treatment market segments, market trends and opportunities, and any further data you may need to thrive in the bone pain treatment market. This bone pain treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The bone pain treatment market includes revenues earned by entities by providing services such as pharmacological therapy services, physical therapy and rehabilitation services, surgical intervention services, pain management clinics, and diagnostic imaging and evaluation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The bone pain treatment also includes sales of acetaminophen, ibuprofen, naproxen, morphine, oxycodone, alendronate, and prednisone. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.